The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo, MD, Vanderbilt University Medical Center, Nashville, TN, discusses a study investigating the side effect profiles of commercially available bispecific antibodies and CAR T-cell therapies to treat multiple myeloma. Based on data from pivotal clinical trials, the analysis found that bispecific antibodies were associated with a shorter duration of cytokine release syndrome (CRS) and neurotoxicity. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
